[go: up one dir, main page]

WO2008148074A3 - Inhibitors of mtor and methods of treatment using same - Google Patents

Inhibitors of mtor and methods of treatment using same Download PDF

Info

Publication number
WO2008148074A3
WO2008148074A3 PCT/US2008/064809 US2008064809W WO2008148074A3 WO 2008148074 A3 WO2008148074 A3 WO 2008148074A3 US 2008064809 W US2008064809 W US 2008064809W WO 2008148074 A3 WO2008148074 A3 WO 2008148074A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
methods
mtor
inhibitors
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/064809
Other languages
French (fr)
Other versions
WO2008148074A2 (en
Inventor
Richard Lin
Dale Drueckhammer
Jun Yong Choi
Lisa Ballou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Foundation of the State University of New York
Original Assignee
Research Foundation of the State University of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Foundation of the State University of New York filed Critical Research Foundation of the State University of New York
Publication of WO2008148074A2 publication Critical patent/WO2008148074A2/en
Publication of WO2008148074A3 publication Critical patent/WO2008148074A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides novel compounds that inhibit mTOR activity. Compositions, including pharmaceutical compositions, comprising compounds of the present invention are also provided. The present invention also provides methods of treatment comprising administering compositions of the present invention to a subject in need thereof.
PCT/US2008/064809 2007-05-24 2008-05-24 Inhibitors of mtor and methods of treatment using same Ceased WO2008148074A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93185807P 2007-05-24 2007-05-24
US60/931,858 2007-05-24

Publications (2)

Publication Number Publication Date
WO2008148074A2 WO2008148074A2 (en) 2008-12-04
WO2008148074A3 true WO2008148074A3 (en) 2009-03-19

Family

ID=40075755

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/064809 Ceased WO2008148074A2 (en) 2007-05-24 2008-05-24 Inhibitors of mtor and methods of treatment using same

Country Status (1)

Country Link
WO (1) WO2008148074A2 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8466151B2 (en) 2007-12-26 2013-06-18 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
CA2730890C (en) 2008-07-17 2018-05-15 Critical Outcome Technologies Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
FR2947551B1 (en) * 2009-07-02 2012-05-18 Sanofi Aventis NOVEL 1,2,3,4-TETRAHYDRO-PYRIMIDO {1,2-A) PYRIMIDIN-6-ONE DERIVATIVES, THEIR PREPARATION AND THEIR PHARMACEUTICAL USE AS AKT PHOSPHORYLATION INHIBITORS (PKB)
JP5680639B2 (en) 2009-07-02 2015-03-04 サノフイ Novel 6-morpholin-4-yl-pyrimidin-4- (3H) -one derivatives and their pharmaceutical preparations as inhibitors of AKT (PKB) phosphorylation
RU2561130C2 (en) 2009-07-02 2015-08-20 Санофи NOVEL DERIVATIVES OF 1,2,3,4-TETRAHYDROPYRIMIDO{1,2-a}PYRIMIDIN-6-ONE, OBTAINING THEREOF AND PHARMACEUTICAL APPLICATION
FR2947550B1 (en) * 2009-07-02 2012-05-18 Sanofi Aventis NOVEL 2,3-DIHYDRO-1H-IMIDAZO {1,2-A} PYRIMIDIN-5-ONE DERIVATIVES, THEIR PREPARATION AND THEIR PHARMACEUTICAL USE AS AKT PHOSPHORYLATION INHIBITORS (PKB)
FR2951173B1 (en) * 2009-10-09 2011-12-02 Sanofi Aventis NOVEL 2,3-DIHYDRO-1H-IMIDAZO {1,2-A} PYRIMIDIN-5-ONE DERIVATIVES, THEIR PREPARATION AND THEIR PHARMACEUTICAL USE AS AKT PHOSPHORYLATION INHIBITORS (PKB)
FR2951174B1 (en) * 2009-10-09 2011-12-02 Sanofi Aventis NOVEL 1,2,3,4-TETRAHYDRO-PYRIMIDO {1,2-A} PYRIMIDIN-6-ONE DERIVATIVES, THEIR PREPARATION AND THEIR PHARMACEUTICAL USE AS AKT PHOSPHORYLATION INHIBITORS (PKB)
JP5680638B2 (en) 2009-07-02 2015-03-04 サノフイ Novel (6-oxo-1,6-dihydropyrimidin-2-yl) amide derivatives, their preparation and their pharmaceutical use as AKT (PKB) phosphorylation inhibitors
JP5663571B2 (en) 2009-07-02 2015-02-04 サノフイ Novel 2,3-dihydro-1H-imidazo {1,2-a} pyrimidin-5-one derivatives, their preparation and their pharmaceutical use
WO2011109833A2 (en) 2010-03-05 2011-09-09 President And Fellows Of Harvard College Induced dendritic cell compositions and uses thereof
US9248110B2 (en) * 2010-03-18 2016-02-02 Steven Lehrer Compositions and methods of treating and preventing lung cancer and lymphangioleiomyomatosis
EP2552915B1 (en) 2010-04-01 2017-07-19 Critical Outcome Technologies Inc. Compounds for the treatment of hiv
FR2969612B1 (en) * 2010-12-23 2013-02-08 Sanofi Aventis NOVEL 2,3-DIHYDRO-1H-IMIDAZO {1,2-A} PYRIMIDIN-5-ONE DERIVATIVES, THEIR PREPARATION AND THEIR PHARMACEUTICAL USE
FR2969613B1 (en) * 2010-12-23 2013-02-08 Sanofi Aventis NOVEL 1,2,3,4-TETRAHYDRO-PYRIMIDO {1,2-A} PYRIMIDIN-6-ONE DERIVATIVES, THEIR PREPARATION AND THEIR PHARMACEUTICAL USE
HUE024504T2 (en) 2010-12-23 2016-01-28 Sanofi Sa Pyrimidinone derivatives, preparation thereof and pharmaceutical use thereof
FR2969608B1 (en) * 2010-12-28 2013-02-08 Sanofi Aventis NOVEL (5-HALO-6-OXO-1,6-DIHYDRO-PYRIMIDIN-2-YL) -AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR PHARMACEUTICAL USE AS AKT PHOSPHORYLATION INHIBITORS (PKB)
FR2969610B1 (en) * 2010-12-28 2013-04-05 Sanofi Aventis NOVEL (6-OXO-1,6-DIHYDRO-PYRIMIDIN-2-YL) -INDOLINAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR PHARMACEUTICAL USE AS AKT PHOSPHORYLATION INHIBITORS (PKB)
FR2969614A1 (en) * 2010-12-28 2012-06-29 Sanofi Aventis New pyrimidinone compounds are akt phosphorylation inhibitors useful for treating e.g. gastric cancer, glioblastomas, thyroid cancer, bladder cancer, breast cancer, melanoma, lymphoid or myeloid hematopoietic tumors, and sarcomas
FR2969607B1 (en) * 2010-12-28 2013-02-08 Sanofi Aventis NOVEL THIOPYRIMIDINONE DERIVATIVES, THEIR PREPARATION AND THEIR PHARMACEUTICAL USE AS PHOSPHORYLATION INHIBITORS OF AKT (PKB)
EP2658844B1 (en) 2010-12-28 2016-10-26 Sanofi Novel pyrimidine derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors
FR2992314B1 (en) 2012-06-22 2015-10-16 Sanofi Sa NOVEL 2,3-DIHYDRO-1H-IMIDAZO {1,2-A} PYRIMIDIN-5-ONE AND 1,2,3,4-TETRAHYDRO-PYRIMIDO {1,2-A} PYRIMIDIN-6-ONE DERIVATIVES COMPRISING A SUBSTITUTED MORPHOLINE, THEIR PREPARATION AND THEIR PHARMACEUTICAL USE
FR2992316A1 (en) 2012-06-22 2013-12-27 Sanofi Sa PYRIMIDINONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
CN110156783B (en) * 2015-07-11 2021-09-07 南京爱德程医药科技有限公司 Pyrimidyl-substituted fused quinolines as PI3K/MTOR inhibitors
CN117615763A (en) * 2021-02-01 2024-02-27 健道生物医药有限公司 Phosphoinositide 3 kinase beta inhibitor, composition and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4661592A (en) * 1984-06-27 1987-04-28 G. D. Searle & Co. 4H-pyrimido[2,1-a]isoquinolin-4-one derivatives
US20070112005A1 (en) * 2005-11-17 2007-05-17 Xin Chen Fused bicyclic mTOR inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4661592A (en) * 1984-06-27 1987-04-28 G. D. Searle & Co. 4H-pyrimido[2,1-a]isoquinolin-4-one derivatives
US20070112005A1 (en) * 2005-11-17 2007-05-17 Xin Chen Fused bicyclic mTOR inhibitors

Also Published As

Publication number Publication date
WO2008148074A2 (en) 2008-12-04

Similar Documents

Publication Publication Date Title
WO2008148074A3 (en) Inhibitors of mtor and methods of treatment using same
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
WO2009129246A3 (en) Compositions and methods for preparing and using same
WO2007087068A3 (en) Inhibitors of tyrosine kinases and uses thereof
WO2012062925A3 (en) Compounds and methods for treating pain
EA200901486A1 (en) COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS
WO2008070041A3 (en) Inhibitors of akt activity
WO2006135627A3 (en) Inhibitors of akt activity
IL225198A (en) Aminotetrahydropyran compounds, pharmaceutical compositions comprising the same and the use thereof for the treatment of diabetes
WO2006091395A3 (en) Inhibitors of akt activity
MX344238B (en) Tetrazole compounds and methods of making and using same.
MX2009006704A (en) New compounds.
AU2012253757A8 (en) Partially saturated tricyclic compounds and methods of making and using same
HK1198869A1 (en) Combination treatments for hepatitis c
WO2012046030A3 (en) Phosphodiesterase inhibitors
ZA201004214B (en) Dipeptidyl peptidase-iv inhibiting compounds,methods of preparing the same,and pharmaceutical compositions containing the same as active agent
WO2011113060A3 (en) Antiviral compounds and methods of use thereof
WO2008076954A3 (en) Heterocycle compounds and methods of use thereof
EA200901484A1 (en) COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS
WO2008097924A3 (en) Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
WO2010121164A3 (en) 1,4-benzodiazepinone compounds and their use in treating cancer
ATE522500T1 (en) AMIDE DERIVATIVES AS ION CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF
WO2006110638A3 (en) Inhibitors of akt activity
WO2010062506A3 (en) Decahydro-1h-indenoquinolinone and decahydro-3h-cyclopentaphenanthridinone cyp17 inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08756262

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08756262

Country of ref document: EP

Kind code of ref document: A2